{"id":"W4413781006","doi":"10.1016/s2152-2650(25)02676-x","title":"MM-1049: DREAMM-7 Study of Belantamab Mafodotin + Bortezomib + Dexamethasone vs Daratumumab + Bortezomib + Dexamethasone in Relapsed/Refractory Multiple Myeloma: Efficacy in Patients by Subsequent Therapy","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Daratumumab; Medicine; Bortezomib; Dexamethasone; Internal medicine; Oncology; Multiple myeloma; Refractory (planetary science)","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002485139,0.001644651,0.003930124,0.000697415,0.0004546023,0.001476786,0.001795512,0.001423202,0.00550151],"category_scores_gemma":[0.00125317,0.000781588,0.003499968,0.0005731089,0.001209349,0.00143269,0.00071901,0.005391027,0.001497689],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001613504,"about_ca_system_score_gemma":0.001900908,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001638045,"about_ca_topic_score_gemma":0.003206644,"domain_scores_codex":[0.9988053,0.0006160556,0.00006685266,0.0001695095,0.0001089238,0.0002333934],"domain_scores_gemma":[0.9989257,0.0002308943,0.0001738431,0.0001020487,0.00004458176,0.0005228448],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9567065,0.01144051,0.001394172,0.0002450535,0.001450205,0.00003703941,0.00005014711,0.0005432043,0.002935394,0.0001682247,0.0007315321,0.02429811],"study_design_scores_gemma":[0.6994033,0.2874676,0.007325609,0.00005669576,0.001529482,0.000110491,0.00005488506,0.0007239986,0.001236669,0.0002140878,0.001835483,0.00004160116],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9875345,0.006634376,0.0003209896,0.0006419659,0.0004628222,0.0007523341,0.00125064,0.00008940324,0.002313003],"genre_scores_gemma":[0.9874735,0.0034704,0.0009040236,0.0008608407,0.0004648467,0.0009403097,0.002390959,0.00003949428,0.003455701],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00550151,"threshold_uncertainty_score":0.01840436,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03211228350000463,"score_gpt":0.3444139536119541,"score_spread":0.3123016701119495,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}